Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model

Virender Kumar, Bharti Sethi, Dalton W. Staller, Prakash Shrestha, Ram I. Mahato

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model'. Together they form a unique fingerprint.

Medicine & Life Sciences